Medication review interventions to reduce hospital readmissions in older people. by Dautzenberg, Lauren et al.
R E V I EW AR T I C L E
Medication review interventions to reduce hospital
readmissions in older people
Lauren Dautzenberg MD, MSc1 | Lisa Bretagne MSc2,3 |
Huiberdina L. Koek MD, PhD1 | Sofia Tsokani MSc4 | Stella Zevgiti PhD4 |
Nicolas Rodondi MD, PhD2,3 | Rob J. P. M. Scholten MD, PhD5 |
Anne W. Rutjes PhD3,6 | Marcello Di Nisio MD, PhD7 |
Renee C. M. A. Raijmann MD, MSc1 | Marielle Emmelot-Vonk MD, PhD1 |
Emma L. M. Jennings MB8,9 | Olivia Dalleur MS, PhD10,11 |
Dimitris Mavridis PhD4,12 | Wilma Knol MD, PhD1
1Department of Geriatric Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
2Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
3Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
4Department of Primary Education, School of Education, University of Ioannina, Ioannina, Greece
5Cochrane Netherlands/Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The
Netherlands
6Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
7Department of Medicine and Ageing Sciences, University G. D'Annunzio, Chieti, Italy
8School of Medicine, University College Cork, National University of Ireland, Cork, Ireland
9Department of Geriatric Medicine, Cork University Hospital, Cork, Ireland
10Louvain Drug Research Institute (LDRI), Clinical Pharmacy Research Group, Université catholique de Louvain—UCLouvain, Brussels, Belgium
11Pharmacy Department, Cliniques universitaires Saint-Luc, Université catholique de Louvain—UCLouvain, Brussels, Belgium
12Sorbonne Paris Cité, Faculté de Médecine, Paris Descartes University, Paris, France
Correspondence
Lauren Dautzenberg, MD, MSc,




European Union's Horizon 2020 research
and innovation programme, Grant/Award
Number: 6342388; Swiss State Secretariat
for Education, Research and Innovation
(SERI), Grant/Award Number: 15.0137
Abstract
Objective: To assess the efficacy of medication review as an isolated interven-
tion and with several co-interventions for preventing hospital readmissions in
older adults.
Methods: Ovid MEDLINE, Embase, The Cochrane Central Register of Con-
trolled Trials and CINAHL were searched for randomized controlled trials
evaluating the effectiveness of medication review interventions with or without
co-interventions to prevent hospital readmissions in hospitalized or recently
discharged adults aged ≥65, until September 13, 2019. Included outcomes were
“at least one all-cause hospital readmission within 30 days and at any time
after discharge from the index admission.”
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Results: Twenty-five studies met the inclusion criteria. Of these, 11 studies
(7,318 participants) contributed to the network meta-analysis (NMA) on all-
cause hospital readmission within 30 days. Medication review in combination
with (a) medication reconciliation and patient education (risk ratio (RR) 0.45;
95% confidence interval (CI) 0.26–0.80) and (b) medication reconciliation,
patient education, professional education and transitional care (RR 0.64; 95% CI
0.49–0.84) were associated with a lower risk of all-cause hospital readmission
compared to usual care. Medication review in isolation did not significantly
influence hospital readmissions (RR 1.06; 95% CI 0.45–2.51). The NMA on all-
cause hospital readmission at any time included 24 studies (11,677 participants).
Medication review combined with medication reconciliation, patient education,
professional education and transitional care resulted in a reduction of hospital
readmissions (RR 0.82; 95% CI 0.74–0.91) compared to usual care. The quality of
the studies included in this systematic review raised some concerns, mainly
regarding allocation concealment, blinding and contamination.
Conclusion: Medication review in combination with medication reconcilia-
tion, patient education, professional education and transitional care, was asso-
ciated with a lower risk of hospital readmissions compared to usual care. An
effect of medication review without co-interventions was not demonstrated.
Trials of higher quality are needed in this field.
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1 | INTRODUCTION
Hospitalizations can have detrimental effects on older
patient outcomes.1,2 Following hospitalization, older
adults are at risk for complications like delirium, falls,
functional decline and subsequent institutionalization or
readmission.1,2 Medication related readmissions occur
frequently, particularly in older adults.3
Improving medication appropriateness may reduce
medication related problems and the number of hospital
readmissions. Medication appropriateness is present
when therapeutic objectives are being achieved or there
is a reasonable chance they will be achieved and the ben-
efits of the medication outweigh the risks for an individ-
ual patient.4 Relevant systematic reviews often
recommend a medication review to improve the quality
of prescriptions in older patients.5-8 Christensen et al con-
ducted a Cochrane review assessing the effect of medica-
tion review in hospitalized patients.9 A medication
review is an intervention which can be implemented in
isolation or in combination with one or more co-inter-
ventions. Co-interventions, i.e., medication reconcilia-
tion, education of patients/healthcare professionals, use
of Computerized Decision Support tool, prescribing
criteria like START/STOPP criteria10 or the Beers'
criteria,11 complement or structure the basic critical eval-
uation of a patient's medication, and may all have a dif-
ferent effects on hospital readmissions.
Key Points
• A medication review in combination with
medication reconciliation, patient education,
professional education and transitional care is
associated with a decreased risk of hospital
readmissions.
• An effect of medication review as an isolated
intervention was not demonstrated.
Why Does this Paper Matter?
A medication review can be implemented in isola-
tion or in combination with co-interventions, such as
medication reconciliation or training of healthcare
professionals. It is unclear whether a medication
review alone or in combination with co-interven-
tions, effectively prevents hospital readmissions.
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Frequently the terms for medication review and co-
interventions as listed previously are erroneously used inter-
changeably. Thus, leading to substantial heterogeneity. Medi-
cation related problems frequently occur on transition from
one health care setting to another.12,13 However, Christensen
et al excluded studies where medication review recommenda-
tions were implemented after discharge.
An internationally accepted standardized approach
for implementing medication reviews in research and
clinical settings is lacking. It is unclear whether a medi-
cation review alone or in combination with co-interven-
tions, effectively prevents hospital readmissions.
Published data are conflicting, possibly due to the hetero-
geneity of the interventions evaluated and the timing of
execution.5,6,14-17 To address this, we categorized all med-
ication review interventions by the presence of associated
co-interventions. A network meta-analysis (NMA) per-
mitted the synthesis of relative effects from studies com-
paring competing interventions, even if these
interventions were not directly compared to each other in
the literature.18,19 We included studies where the inter-
vention was implemented during admission or within
2 weeks of discharge.
The aim of this systematic review and NMA was to deter-
mine and compare the impact of medication review in isola-
tion or with co-interventions, during hospitalization or within
2 weeks of discharge, on hospital readmissions.
2 | METHODS
2.1 | Protocol
The study protocol was registered online (PROSPERO,
registration number CRD42020150799).
2.2 | Study identification
Replicating the search strategy of Christensen et al9 we
searched online repositories Ovid MEDLINE, Embase,
The Cochrane Central Register of Controlled Trials and
CINAHL from January 1 2014 to September 13 2019,
without language restriction (Tables S11–S14). Original
studies of Christensen et al were identified via reference
lists and rescreened. Bibliographical hand searches of rel-
evant systematic reviews were also conducted.7-9,15,17,21-27
2.3 | Eligibility criteria
Controlled trials (randomized, quasi and cluster) evaluat-
ing the effectiveness of medication review interventions
with or without co-interventions to prevent hospital
readmissions in adults aged 65 years and older were
included. Participants were hospitalized or recently dis-
charged (the medication review was conducted within
2 weeks of discharge) to the community, nursing home
or rehabilitation center. Comparison treatments were
usual care, a sham intervention or another version of a
medication review intervention.
Included outcomes were (i) at least one all-cause hos-
pital readmission, (ii) at least one medication-related
readmission at any time, and (iii) all-cause hospital
readmission rate. Details of the study population, inter-
ventions, comparators and outcomes are described in
Table S10.
2.4 | Study selection
Study selection was performed by two researchers
(LD and LB). A supervised test screening (RJPMS) of
application of inclusion criteria was conducted prior to
the start of the title/abstract screening phase and the full
text screening phase to ensure consistency, i.e., 50 studies
with 98% agreement between researchers. Each
researcher independently screened half of the titles and
abstracts identified by the systematic search. Each
researcher subsequently independently screened half of
the included full texts for inclusion. Uncertainties were
resolved by discussion or by involvement of a third
author (WK, RJPMS, HLK). Several publications from
the same patient cohort were considered as one study
with one or more companion reports.
2.5 | Data extraction
One researcher (LD) extracted all descriptive and out-
come data. Outcome data were verified by a second
researcher (LB). Conflicts were discussed and resolved by
the two researchers. For every included study data was
extracted by means of a bespoke report-form capturing
study design, population characteristics, intervention
characteristics and reported outcomes (Table S15).
Reported interventions were categorized into nine
intervention components: medication review, medication
reconciliation, shared decision making, patient educa-
tion/ medication counseling, health professional educa-
tion, use of validated methods, use of Computerized
Decision Support, compliance aid and transitional care
(Tables 1 and S1). The list of the nine intervention com-
ponents was developed during the preparation of the
study protocol. The list is based on medication review
interventions in previously published RCTs and clinical
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experience of several pharmacologists among the co-
authors. One researcher (LD) categorized the interven-
tions of the included studies by this list. A second
researcher (HLK) blindly evaluated this categorization
for a random sample of included studies (n = 10, 40%),
and there was a 90% overlap. Inconsistencies were solved
during a consensus meeting. Information about the co-
interventions found in the included studies is presented
in Table S2.
2.6 | Risk of bias assessment
The risk of bias assessment was performed using the
Effective Practice and Organization of Care (EPOC) ver-
sion of Cochrane's Risk of Bias tool.20 The risk of bias
assessment was performed by one researcher (LD) and
verified by a second researcher (LB). Discrepancies were
discussed and resolved.
2.7 | Data analysis
When the number of included studies was sufficient
(i.e., less interventions than studies providing data), we
performed random-effects NMA for each of the afore-
mentioned outcomes using the netmeta command in R
Statistical Software (Team RC. R: A language and envi-
ronment for statistical computing. Vienna, Austria: R
Foundation for Statistical Computing, 2013).18,19,21,22
After categorization of the interventions of included stud-
ies (Table 1), many studies turned out to consist of multi-
component interventions (e.g., medrev + medrec
+ pedu). Therefore, as per protocol, we additionally ana-
lyzed the effect of the (combination of) components, also
known as component NMA (CNMA) (for details: see
Supplement, additional information regarding NMA).23
We calculated risk ratios (RRs) along with their 95%
confidence intervals (CIs) for each intervention versus
usual care. For each outcome we used P-scores to rank
intervention effects.23 P-scores measure the certainty that
an intervention is better than the competing interventions
of the network, and take values between 0 and 1; the
higher the P-score, the more beneficial the intervention.
We did not check for inconsistency, i.e., the occurrence of
conflicting direct and indirect evidence, as for none of the
interventions versus usual care there was both direct and indi-
rect evidence available. We assessed transitivity clinically.18
Further subgroup analyses (participants aged
≥75 years, multi-morbid participants and nursing home
residents) were not feasible due to the low number of
studies identified.
2.8 | Confidence in the NMA results
We evaluated the credibility of the NMA results using the
CINeMA approach.24 CINeMA is an online web applica-
tion, considering six domains (within-study bias, across-
study bias, indirectness, imprecision, heterogeneity, and
incoherence) to judge the confidence on NMA results. For
each treatment comparison we rated the corresponding
treatment effect on each of the aforementioned six
domains as either “no concerns”, “minor concerns,” or
“major concerns” (for details: see online Supplement, addi-
tional information regarding the CINeMA approach).
3 | RESULTS
3.1 | Study selection
We identified 4,045 studies through database search.
Figure S1. illustrates study identification and selection.
Five additional RCTs were identified, two25,26 from the
list of excluded studies of Christensen et al and three 27-29
from screening reference lists of 12 relevant systematic
reviews. After screening, 25 studies25-49 and one compan-
ion report50 were included in the final analysis.
3.2 | Study and participant
characteristics
An executive summary of included study and participant
characteristics is presented in Table 2. (detailed individ-
ual study description is available in Tables S2 and S3). In
12 studies (48%)26,28,31,33,36-38,43-45,48,49, the mean/median
age was 75–84 years and in four studies (16%)
≥85 years.25,29,32,34 In the majority of the studies, at least





Shared decision making Sdm
Patient education/medication counseling Pedu
Health professional education Hpedu
Use of validated methods Vm
Use of Computerized Decision Support Cds
Compliance aid Ca
Transitional care Tc
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TABLE 2 Summary of participant and study characteristics of the 25 included randomized controlled trials
Participant or study characteristic Number of studies (%)
Citation number for each study in
each row
Mean/median age (years)
65–74 9 (36%) 27,30,35,39-42,46,47
75–84 12 (48%) 26,28,31,33,36-38,43-45,48,49
≥85 4 (16%) 25,29,32,34
Female (%)
25–49 5 (20%) 30,34,42,46,47
50–74 19 (76%) 25-29,31-33,35-40,43-45,48,49
Not reported 1 (4%) 41
Year of publication
2000–2004 1a (4%) 28
2005–2009 5a (20%) 26,27,29,32,41
2010–2014 3a (12%) 25,38,45
2015–2019 16 (64%) 30,31,33-37,39,40,42-44,46-49
Continent
Europe 16 (64%) 25,26,43-46,48,49,27,
29,30,32,37,38,41,42
North America 6 (24%) 30,31,34,35,42,49
Australia/New Zealand 1 (4%) 28
South America 1 (4%) 46
Asia 1(4%) 48
Study design
Parallel 19 (76%) 25,27-29,31-34,36-42,45-47,49
Quasi randomized 4 (16%) 26,35,44,48
Cluster 2 (8%) 30,43
Site
Single center 17 (68%) 26-28,30-32,34,36-38,42,44-49
Multicenter 8 (32%) 25,29,33,35,39-41,43
Setting
Hospital 21 (84%) 25-27,30-41,44-49
Community 3 (12%) 28,29,42
Community pharmacy 1 (4%) 43
Duration of follow-up (weeks)
0–4 7 (28%) 30,34,35,44,46,47,49
5–12 6 (24%) 28,31,37,38,42,48
13–26 7 (28%) 25,27,29,33,40,43,45
27–52 5 (20%) 26,32,36,39,41
Sample size
<100 4 (16%) 34,36-38
100–499 16 (64%) 26-28,30-33,39,42-49
500–999 3 (12%) 25,29,41
≥1,000 2 (8%) 35,40
Regular used medication, mean/median number
0–5 0
(Continues)
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half of the study population was female (n = 19,
76%).25-29,31-33,35-40,43-45,48,49
In four studies (16%),28,29,42,43 the intervention was
community based within 2 weeks of discharge. The
duration of follow-up of all studies varied from
4 weeks to 1 year. Study size ranged from 22 to 4,049,
over half (n = 21, 84%) of included studies had a study
population ≥ 100.25-33,35,39-49 The mean/median num-
ber of regularly used medication was at least 6 and in
most studies ranged between 6 and 10 (n = 18,
72%).25-30,32,33,35,37-40,43,44,46-48
A summary of the characteristics of the medication
review interventions is provided in Table S5.
3.3 | Risk of bias of included studies
Individual risk of bias assessments of included studies are
presented in Table S4 and the aggregate risk of bias
assessment per domain in Figure S2.
Most studies had a low risk of bias for the domains
“random sequence generation” (n = 19,
76%)25,27-29,31-34,36-42,45-47,49, “similarity of baseline charac-
teristics” (n = 24, 96%)25-32,34-49 and “other bias” (n = 20,
80%).25-27,29,31-40,42,44-48 Allocation concealment was
adequately performed in one third, inadequately in
one third and unclear in the remaining third of the
trials. In 76% of the studies, no information was
reported at baseline on hospital (re)admissions in the
preceding months (n = 19).27,29-39,42-48 Blinding of
participants or personnel was not performed in the
majority of studies. Blinded outcome assessment was
performed in 17 studies (68%).25,26,28-30,32-37,39-41,45-47
In 19 studies (76%) there was a high risk of bias for
contamination.25-29,31-34,36-40,42,45,47-49 For the
domains “incomplete outcome data” (n = 16,
64%)25,27-38,40,42,47 and “selective outcome reporting”
(n = 13, 52%),26,30-33,36,37,39,40,42,44,45,49 more than
half of the studies scored a low risk of bias.
3.4 | Network meta-analysis
NMA was performed for the outcomes “all-cause hospital
readmissions within 30 days” and “all-cause hospital
readmissions at any time.” There was insufficient
reported data to perform a NMA for other outcomes as
the number of interventions evaluated was higher than
the number of studies providing data.
3.4.1 | All-cause hospital readmissions
within 30 days
For the outcome “at least one all-cause hospital
readmission within 30 days after discharge,” the NMA
included 11 studies (7,318 participants)30,31,33-35,40,44,46-49
and 10 interventions that were all compared with usual
care (Figure S3). Each intervention was directly com-
pared to usual care, except for the medication review
intervention without any co-interventions, for which
only indirect evidence was present. The RRs and 95%
CIs for every intervention versus usual care, resulting
from the primary analysis in which each existing combi-
nation of components was analyzed as a distinct inter-
vention, are presented in Table 3 and Figure 1.
Two interventions were associated with a statisti-
cally significant decrease in hospital readmissions:
(a) medication review in combination with medication
reconciliation and patient education (RR 0.45; 95% CI
0.26–0.80; P-score 0.92) and (b) medication review in
combination with medication reconciliation, patient
education, professional education and transitional care
(RR 0.64; 95% CI 0.49–0.84; P-score 0.76).
TABLE 2 (Continued)
Participant or study characteristic Number of studies (%)
Citation number for each study in
each row
6–10 18 (72%) 25-30,32,33,35,37-40,43,44,46-48
11–15 1 (4%) 42
>15 2 (8%) 34,36
Not reported 4 (16%) 31,41,45,49
Chronic conditions, mean/median number
0–5 4 (16%) 25,28,43,46
Not reported 21 (84%) 26,27,29-42,44,45,47-49
aThese studies were identified from screening the reference list of relevant systematic reviews and the list of included and excluded studies by Christensen et al.
The studies identified through database search were all published after 2014.
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Analysis of effects of single components (Table S7)
showed that patient education significantly reduced hos-
pital readmissions (RR 0.64; 95% CI 0.41–0.99).
Analysis of effects of the compound interventions
(interventions rebuilt by adding up the separate
effects of the components) (Table S6) demonstrated a
TABLE 3 Risk ratios with 95% confidence intervals (95% CIs), P-scores and CINeMA confidence ratings for the interventions versus















All-cause hospital readmissions within 30 days
mdrev + mdrec + pedu 1 207 0.45 (0.26–0.80) 0.92 Lowb,c Moderated,e
mdrev + pedu + tc 1 104 0.59 (0.18–1.91) 0.67 Lowb,c Moderatee,f
mdrev + mdrec + pedu + hpedu + tc 1 1,467 0.64 (0.49–0.84) 0.76 Lowb,c Moderated,e
mdrev + cds 1 254 0.73 (0.43–1.22) 0.61 Lowb,c Moderated,e,f
mdrev + mdrec + tc 1 429 0.79 (0.52–1.22) 0.52 Lowb,c Lowd,e,f,g
mdrev + mdrec 2 4,201 0.88 (0.72–1.07) 0.40 Lowb,c Moderated,e,f
mdrev + mdrec + hpedu + vm 1 166 0.88 (0.59–1.31) 0.40 Lowb,c Moderatee,f
mdrev + tc 2 380 0.89 (0.55–1.42) 0.39 Lowb,c Moderatee,f
mdrev + hpedu 1 1,467 0.89 (0.70–1.14) 0.37 Lowb,c Moderated,e,f
mdrev 0 NA 1.06 (0.45–2.51) 0.26 Lowb,c Moderated,f,g
All-cause hospital readmissions at any time
mdrev + pedu + tc 1 104 0.59 (0.18–1.91) 0.78 Lowb,c Moderatef
mdrev + pedu + mdt + tc 1 121 0.62 (0.38–1.02) 0.90 Lowb,c High
mdrev + mdrec + pedu 1 207 0.76 (0.55–1.04) 0.80 Lowb,c High
mdrev + mdrec + pedu + hpedu + tc 2 2,229 0.82 (0.74–0.91) 0.77 Lowb,c High
mdrev + mdrec + hpedu + vm 1 166 0.88 (0.59–1.31) 0.61 Lowb,c Moderatef
mdrev + tc 2 380 0.89 (0.55–1.42) 0.59 Lowb,c Moderatef
mdrev + mdrec + pedu + tc 3 1,205 0.91 (0.79–1.04) 0.60 Lowb,c High
mdrev + mdrec 5 4,708 0.92 (0.82–1.05) 0.56 Lowb,c High
mdrev + mdrec + tc 1 429 0.94 (0.74–1.19) 0.52 Lowb,c Moderatef,g
mdrev + hpedu 1 1,467 0.97 (0.86–1.10) 0.46 Lowb,c High
mdrev + mdrec + pedu + hpedu 1 141 1.01 (0.58–1.76) 0.44 Lowb,c Moderatef,g
mdrev + pedu + cds + tc 1 345 1.02 (0.82–1.26) 0.39 Lowb,c Moderated,f
mdrev + cds 2 554 1.02 (0.79–1.31) 0.40 Lowb,c Moderatef
mdrev + pedu + hpedu + ca + tc 1 855 1.22 (1.01–1.46) 0.17 Lowb,c High
mdrev 0 NA 1.50 (0.84–2.69) 0.13 Lowb,c Moderated,f,g
mdrev + mdrec + pedu + hpedu +
vm + tc
1 123 2.22 (1.29–3.83) 0.02 Lowb,c High
Abbreviations: mdrev, medication review; mdrec, medication reconciliation; pedu, patient education/medication counseling; hpedu, health professional
education; vm, use of validated methods; cds, use of Computerized Decision Support; ca, compliance aid; tc, transitional care.
aThe result of the assessment for the domains “within-study bias” and “reporting bias” was the same for every comparison, i.e., major concerns for “within-
study bias” and “reporting bias” was suspected (first column). To maintain a distinctive character, the remaining four of the six planned domains were taken
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statistically significant effect for (a) medication review
in combination with medication reconciliation and
patient education (RR 0.54; 95% CI 0.35–0.85) and
(b) medication review in combination with medica-
tion reconciliation, patient education, professional
education and transitional care (RR 0.63; 95% CI
0.48–0.82).
3.4.2 | All-cause hospital readmissions at
any time
For the outcome “at least one all-cause hospital
readmission at any time,” the NMA included 24 studies
(11,677 participants)25-35,37-49 and 17 interventions
(Figure S4). All interventions consisting of multiple com-
ponents were compared with usual care. There was no
direct evidence for medication review without any co-
interventions versus usual care. Table 3 and Figure 2 pre-
sent the RRs for each intervention versus usual care from
the primary analysis. The combination of medication
review, medication reconciliation, patient education, pro-
fessional education and transitional care, was associated
with a statistically significant reduction of hospital
readmission at any time (RR 0.82; 95% CI 0.74–0.91; P-
score 0.77).
Two interventions were associated with a statistically
significant increase of hospital readmissions: (a) medication
review in combination with patient education, professional
education, compliance aid and transitional care (RR 1.22;
95% CI 1.01–1.46; P-score 0.17) and (b) medication review
in combination with medication reconciliation, patient
education, professional education, use of validated
methods and transitional care (RR 2.22; 95% CI 1.29–3.83;
P-score 0.02).
For the separate components and for the compound
interventions, there were no statistically significant
effects on hospital readmissions (Tables S8 and S9).
We performed an additional pairwise meta-
analysis for those studies in which medication review
was performed after discharge, to compare the effect
of a medication review in general with usual care.
NMA was not possible due to the limited number of
studies (n = 4). Medication review had no statistically
significant effect on hospital readmissions at any time,
when compared to usual care (RR 1.14; 95% CI
0.75–1.74).
3.5 | Confidence in the NMA results
For all comparisons, major concerns for “within-study
bias” and “reporting bias” were present, mainly due to
lack of blinding of personnel and participants (which is
the result of the nature of the intervention) and due to
the fact that there are no established statistical methods
to explore reporting bias, respectively, resulting in low
overall confidence in all effects. To allow for discrimina-
tion based on the other domains, we also assessed the
confidence rating for every comparison by only taking
into account the ratings for the remaining four domains.
Table 3 presents these confidence ratings for every inter-
vention versus usual care, along with the reason(s) for
downgrading. Based on these four domains only, the
FIGURE 1 Summary risk ratios (RRs) with 95% confidence intervals (95% CIs) resulting from the primary network meta-analysis for
every intervention consisting of one or more components versus usual care for the outcome all-cause hospital readmissions within 30 days,
including 11 studies. Abbreviations: mdrev, medication review; mdrec, medication reconciliation; pedu, patient education/medication
counseling; hpedu, health professional education; vm, use of validated methods; cds, use of Computerized Decision Support; ca, compliance
aid; tc, transitional care
8 DAUTZENBERG ET AL.
confidence in the NMA results was moderate to high for
the majority of the comparisons.
4 | DISCUSSION
This systematic review and NMA updated current litera-
ture on the effect of different medication review interven-
tions during hospital admission and transition of care, on
prevention of hospital readmissions in participants aged
65 years and older.9 Medication review in combination
with medication reconciliation and patient education was
associated with a significant reduction of all-cause hospi-
tal readmissions within 30 days. This also applied for
medication review in combination with medication rec-
onciliation, patient education, professional education and
transitional care. Medication review as an isolated inter-
vention had no significant effect on hospital
readmissions. This comparison was based on the NMA
with indirect evidence. In this review, most studies com-
pared active interventions to usual care, resulting in most
effect estimates being informed either by direct or indi-
rect evidence. Hence, most effect estimates are imprecise.
This was evidenced both by the wide 95% CI and the
CINeMA analysis where non-significant effect estimates
extended to clinically relevant regions (RR < 0.8 or
RR > 1.25). In the CNMA, the RR for medication review
as an isolated intervention was also not statistically
significant. For the outcome “at least one all-cause hospi-
tal readmission at any time,” medication review in com-
bination with medication reconciliation, patient
education, professional education and transitional care
was associated with a statistically significant reduction,
although the risk reduction was less pronounced than for
hospital readmissions 30 days after discharge. An effect
of medication review as an isolated intervention or per-
formed after discharge was not demonstrated.
A number of previous studies have highlighted the
importance of co-interventions.7,12,15,40 Multifaceted pro-
grams including a medication review, medication recon-
ciliation, patient counseling and follow-up by primary
care physician, pharmacists, and nursing home physi-
cians, reduced the risk of hospital readmissions.12,40 A
previous meta-analysis on the effectiveness of medication
review as an isolated short-term intervention also found
no effect on hospital admissions.5
The two combinations of intervention components
that were associated with a statistically significant
increase of hospital readmissions at any time, were both
investigated by one study each, with a high summary risk
of bias and were directly compared to usual care.29,43 In
these two studies, possible explanations for this unex-
pected finding were (a) an increase of help seeking
behavior after disease-specific education from the phar-
macist leading to better recognition of warning signs,
(b) more adverse events as a result of improved
FIGURE 2 Summary risk ratios (RRs) with 95% confidence intervals (95% CIs) resulting from the primary network meta-analysis for
every intervention consisting of one or more components versus usual care for the outcome all-cause hospital readmissions at any time,
including 24 studies. Abbreviations: mdrev, medication review; mdrec, medication reconciliation; pedu, patient education/medication
counseling; hpedu, health professional education; vm, use of validated methods; cds, use of Computerized Decision Support; ca, compliance
aid; tc, transitional care
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compliance, (c) study-related involvement in medication
management may have increased the complexity of care
causing anxiety, confusion or dependence on health ser-
vices, or (d) chance (type I error).29,43
A strength of this study is the application of standard
NMA as well as CNMA, in which we determined the
effect of both the individual intervention components
and the combinations of these components. Medication
review is a very heterogeneous strategy and we investi-
gated which particular combination of components of a
medication review was most effective. An additional
advantage of NMA is the ranking of interventions
according to their effectiveness using P-scores.
Another strength is that we focused both on studies
in which the intervention was implemented during
admission and studies that applied the intervention
within 2 weeks of discharge. By including the latter stud-
ies, the medication review was performed at a time
period in which the risk of medication related harm or
medication errors is expected to be the highest
(i.e., during transition of care).12,13
This study has some limitations relating to the studies
we included. The quality of the included studies raised
some concerns. In two third of the studies, the risk of bias
for allocation concealment was high or unclear. How-
ever, baseline characteristics were similar between study
arms in all but one study,33 indicating that randomiza-
tion worked well. Although blinding of participants or
personnel was not possible due to the nature of the inter-
ventions, blinded outcome assessment was performed in
68% of the studies. In addition, the outcome of hospital
readmissions is a fairly objective outcome as often data
on hospital readmissions was extracted from national
registers. We also noted a high risk of bias for contamina-
tion in 76% of the studies: the pharmacist's recommenda-
tions in the intervention group probably have led to a
learning effect for the prescriber, and this may have also
influenced the way the prescriber managed the medica-
tion in the control group. This type of bias, however, may
have resulted in an underestimation of the intervention
effect in those studies.
Also, we found that the majority of the studies did
not report on mean number of chronic conditions, medi-
cation appropriateness and number of recommendations
following the medication review, while this information
may give an indication of the potential effect of the medi-
cation review. The use of different inclusion criteria
regarding polypharmacy, use of a specific drug class and
comorbidities, might also impact the effect of the
intervention.
There were some limitations to the review process.
The outcome all-cause hospital readmissions at any time
is inherently heterogeneous. We accepted any time point
for hospital readmissions which ranged from 1 month to
1 year after intervention. This heterogeneity may explain
why the effect of medication review interventions was
more pronounced for the outcome hospital readmissions
within 30 days than readmissions at any time.
The evaluation of many (combinations of) interven-
tion components permitted identification of the most
effective combination. However, this also may have
decreased the power of the analyses, due to the large
number of components relatively to the low number of
studies. A second reason for a reduced power of the ana-
lyses is the previously mentioned fact that most effect
estimates were informed either by direct or indirect
evidence.
The results of this study showed that it is not the
medication review in itself, medication reconciliation,
patient education, healthcare professional education and
transitional care are essential elements that need to be
implemented in clinical practice to reach effect on hospi-
tal readmissions.
For future studies, we advise adequate allocation con-
cealment and we suggest to report on hospital (re)admis-
sions in the preceding months at baseline, as multiple
previous hospital (re)admissions are associated with an
increased risk for readmissions.51
In the included studies, follow-up duration was het-
erogeneous and often short. To determine the effect of a
medication review in both the short and long term, we
recommend that future studies pursue longer follow-up
duration. Outcome definition, including "hospital
readmissions,” was very heterogeneous.52 Use of a
recently published core outcome set for clinical trials of
medication review could overcome this challenge and
enable NMA.53 Furthermore, we recommend future
studies that perform a medication review after hospital
discharge to confirm the current finding of no effect of
this intervention on hospital readmissions. Finally, we
propose to focus on participants with multi-morbidity,
polypharmacy and increasing age (>75 years), who are
at higher risk of medication related problems and medi-
cation errors, but have been poorly represented in
studies.
5 | CONCLUSION
This systematic review and NMA demonstrates that med-
ication review in combination with medication reconcili-
ation, patient education, professional education and
transitional care is associated with a decreased risk of
hospital readmissions within 30 days, compared to
usual care. Therefore it is important to combine it with
these co-interventions when implementing a
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medication review. An effect of medication review as
an isolated intervention or performed after discharge
could not be demonstrated. The effect of a medication
review with co-interventions on hospital readmissions
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